RE:RE:RE:RE:Ipsen hires David Meek as CEOfaraj69 wrote: I'll tell you how much...
https://www.bloomberg.com/news/articles/2016-01-19/ipsen-to-step-up-deal-making-scout-for-new-cancer-products
Also fits the timeline for FDA approval for MCNA.
Can an all mean nothing but I'm just saying.
Again, the CEO who promoted such strategy was no longer the CEO of Ipsen.
i am sure TST was the top contender for a purchase offer from Ipsen up till probably the 2nd FDA results in april. but that 5 years estimated commerclization timeline just completely turned the table.
the way i look at it, we do not know the details of the FDA meeting results, but we know according to the new release, TST estimated it will take at least 5 years for the drug to be commercialized(in another word, making money), and i believe that is on the optimistic side. IF there is some sort of deal going on between Ipsen and TST NOW, it wil not likely a one time cash purchase of the drug as that is at least a 5 years more financial obligations for Ipsen for more clinical trials with no promising results at sight, it will likely more or less a deal that is structured in a way that Ipsen will phase in their investment and expertise in 5 years time and help guide TST towards their final commercialization and market access.----that is somehwat TST is hinting in their new release that its looking for - a PARTNERSHIP. so that Ipsen does not dig itself too deep of a finacial holes, and TST will get by and see what happens in 5 years time.
so IF there is a deal going on between Ipsen and TST, best case scenerio, it will be more cash injection with tighter string attached, so Ipsen will have a say in the path forward and have a bigger pie in the end without too much commiment at the moment, worse case scenerio, the partnership will be based on Ipsen's intangible investment,i.e ispen will promise expertise and market access at the current stage, in exchange for potential financial commitment down the road, and bigger pie at the end.
either way, I suspect we will see a jump on the shareprice once the deal is announced, but manage your expectations, not going to be a happy retirement moment